Meyahealth
HomeGeneticsGeneGCH1 gene
Back to Gene
GCH1 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GCH1 Gene: GTP Cyclohydrolase 1

The GCH1 gene provides instructions for making an enzyme essential for producing tetrahydrobiopterin (BH4), a cofactor critical for neurotransmitter production and amino acid processing. Mutations in this gene can lead to conditions such as dopa-responsive dystonia and tetrahydrobiopterin deficiency.

Overview & Normal Function

The GCH1 gene (also known as GTP cyclohydrolase 1) provides instructions for making an enzyme called GTP cyclohydrolase 1. This enzyme is involved in the first of three steps in the production of a molecule called tetrahydrobiopterin (BH4). Other enzymes help carry out the second and third steps in this process.

Tetrahydrobiopterin plays a critical role in processing several protein building blocks (amino acids) in the body. Specifically, it works with the enzyme phenylalanine hydroxylase to convert an amino acid called phenylalanine into another amino acid, tyrosine. Because it helps enzymes carry out chemical reactions, tetrahydrobiopterin is known as a cofactor.

Tetrahydrobiopterin is also involved in reactions that produce chemicals called neurotransmitters, which transmit signals between nerve cells in the brain. Specifically, it is involved in the production of two neurotransmitters:

  • Dopamine: Transmits signals within the brain to produce smooth physical movements.
  • Serotonin: Regulates mood, emotion, sleep, and appetite.

Health Conditions Related to Genetic Changes

Dopa-Responsive Dystonia

More than 140 mutations in the GCH1 gene have been found to cause dopa-responsive dystonia. This condition is characterized by a pattern of involuntary muscle contractions (dystonia), tremors, and other uncontrolled movements. It usually responds to treatment with a medication called L-Dopa.

Dopa-responsive dystonia results when one copy of the GCH1 gene is mutated in each cell. Most GCH1 gene mutations that cause this condition change single amino acids in the GTP cyclohydrolase 1 enzyme. Researchers believe that the abnormal enzyme may interfere with the activity of the normal version of GTP cyclohydrolase 1 that is produced from the copy of the gene with no mutation. As a result, the amount of working enzyme in affected individuals is reduced by 80 percent or more. A reduction in functional GTP cyclohydrolase 1 enzyme causes less dopamine and serotonin to be produced, leading to the movement problems and other characteristic features of dopa-responsive dystonia.

Tetrahydrobiopterin Deficiency

At least seven mutations in the GCH1 gene have been found to cause tetrahydrobiopterin deficiency. When this condition is caused by GCH1 gene mutations, it is known as GTP cyclohydrolase 1 (GTPCH1) deficiency. GTPCH1 deficiency accounts for about 4 percent of all cases of tetrahydrobiopterin deficiency.

GTPCH1 deficiency results when two copies of the GCH1 gene are mutated in each cell. Most of the mutations responsible for this condition change single amino acids in GTP cyclohydrolase 1. These mutations greatly reduce or eliminate the activity of this enzyme. Without enough GTP cyclohydrolase 1, little or no tetrahydrobiopterin is produced. As a result, this cofactor is not available to participate in chemical reactions such as the conversion of phenylalanine to tyrosine.

If phenylalanine is not converted to tyrosine, it can build up to toxic levels in the blood and other tissues. Nerve cells in the brain are particularly sensitive to phenylalanine levels, which is why excessive amounts of this substance can cause brain damage. Additionally, a reduction in GTP cyclohydrolase 1 activity disrupts the production of certain neurotransmitters in the brain. Because neurotransmitters are necessary for normal brain function, changes in the levels of these chemicals contribute to intellectual disability in people with GTPCH1 deficiency.

Tetrahydrobiopterin deficiency is more severe than dopa-responsive dystonia likely because both copies of the GCH1 gene are mutated, which leads to a more severe enzyme shortage than in dopa-responsive dystonia, in which only one copy of the gene has a mutation.

Other Names for This Gene

  • DYT5
  • DYT5a
  • GCH
  • GCH1_HUMAN
  • GTP cyclohydrolase 1 (dopa-responsive dystonia)
  • GTPCH1

Genomic Location

The GCH1 gene is found on chromosome 14.

Frequently Asked Questions

key distinguishing feature is the diurnal fluctuation of symptoms, where movement difficulties are noticeably worse at the end of the day or after physical activity and improve with rest. Unlike cerebral palsy, which typically presents with spasticity (stiffness) and does not fluctuate significantly throughout the day, dopa-responsive dystonia involves dystonia (sustained muscle contractions) and often includes a history of delayed walking or toe-walking. A definitive diagnostic clue is the rapid and significant improvement in movement after a trial of L-Dopa, which does not occur in cerebral palsy.
If left untreated, dopa-responsive dystonia often progresses to severe disability, with symptoms worsening in the legs and potentially affecting the arms and trunk. However, the condition is highly treatable. Most patients experience a dramatic and often complete reversal of symptoms when started on low-dose L-Dopa therapy. Early diagnosis is critical because long-term untreated dystonia can lead to permanent structural changes in the spine, such as scoliosis, which may not fully resolve even after the movement disorder is controlled.
Dopa-responsive dystonia is caused by an autosomal dominant mutation in the GCH1 gene, meaning only one copy of the mutated gene is needed to cause the condition. However, it exhibits incomplete penetrance, which means that some family members who carry the mutation may never develop symptoms or may have very mild, undiagnosed issues. Genetic counseling is recommended for parents and siblings to understand the 50% risk of inheritance and to discuss the possibility of genetic testing for at-risk relatives, especially if they exhibit subtle movement abnormalities.
The GCH1 gene mutation reduces the production of tetrahydrobiopterin (BH4), a cofactor essential for the synthesis of dopamine. Dopamine is the primary neurotransmitter responsible for smooth, coordinated movement in the basal ganglia of the brain. When BH4 levels are low, dopamine production is insufficient, leading to the uncontrolled muscle contractions and postures characteristic of dystonia. The condition is termed "dopa-responsive" because administering L-Dopa, a precursor to dopamine, bypasses the enzymatic block and restores neurotransmitter levels, thereby alleviating the movement symptoms.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ